| Company Name: |
T&W GROUP |
| Tel: |
021-61551611 13296011611 |
| Email: |
contact@trustwe.com |
N4-Benzoyl-3'-deoxycytidine manufacturers
|
| | N4-Benzoyl-3'-deoxycytidine Basic information |
| Product Name: | N4-Benzoyl-3'-deoxycytidine | | Synonyms: | N4-Benzoyl-3'-deoxycytidine;N4-Benzoyl-3'-deoxy-D-cytidine;N-(1-((2R,3R,5S)-3-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide;Cytidine, N-benzoyl-3'-deoxy- (9CI);N-?benzoyl-?3'-?deoxy-(9CI)Cytidine;N4-Benzoyl-3'-deoxycytidine;N4-Benzoyl-3′-deoxycytidine, CAS 161110-00-5 | | CAS: | 161110-00-5 | | MF: | C16H17N3O5 | | MW: | 331.32 | | EINECS: | | | Product Categories: | | | Mol File: | 161110-00-5.mol |  |
| | N4-Benzoyl-3'-deoxycytidine Chemical Properties |
| density | 1.50±0.1 g/cm3(Predicted) | | pka | 8.65±0.20(Predicted) |
| | N4-Benzoyl-3'-deoxycytidine Usage And Synthesis |
| Chemical Properties | White to off-white crystalline powder | | Uses | N4-Benzoyl-3’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | N4-Benzoyl-3'-deoxycytidine Preparation Products And Raw materials |
|